AP32573-A-A - 072396.0203

THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 0 6 2001

TECH CENTER 1600/2900

Serial No.

Applicants

09/653,182

Robbins et al.

Examiner: to be assigned

Filed

August 31, 2000

Group Art Unit: 1645

For

IDENTIFICATION OF PEPTIDES THAT FACILITATE UPTAKE AND CYTOPLASMIC AND/OR NUCLEAR TRANSPORT OF PROTEINS,

DNA AND VIRUSES

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231

February 28, 2001 Date of Deposit

Alicia A. Russo

Attorney Name

Registration No.

February 28, 2001 Date of Signature

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, Applicants respectfully request that the references relating to the above-mentioned application listed herein in reverse chronological order be made of record in the U.S. Patent and Trademark Office. The referenced citations are listed in the accompanying PTO Form-1449 and copies of the references are provided in the accompanying binder. A copy of the International Search Report for the corresponding PCT application is also provided.

U.S. Patents:

1. U.S. Patent 5,338,665.

RECEIVED

MAR 0 6 2001

TECH CENTER 1600/2900

Foreign Patents:

- 1. WO 99/10485
- 2. WO 99/06542
- 3. EP 0903408
- 4. WO 98/51825
- 5. WO 98/51325

Other References:

- 1. Schwarze and Dowdy, 2000, *TIPS 21*: 45-48.
- 2. Elliot and O'Hare, 2000, *J. Virol.* 74: 2131-2141.
- 3. Branden et al., 1999, Nat. Biotechnol. 17: 784-787.
- 4. Brown & Wauters, 1999, Cancer Res. 59: 1391-1399.
- 5. Ellerby et al., 1999, *Nat. Med.* 5: 1032.
- 6. Derer et al., 1999, *J. Mol. Med.* 77: 609-613.
- 7. Gambotto et al., 1999, Cancer Gene Ther. 6: 45.
- 8. Hiroshi et al., 1999, Gene Ther. 6: 1988.
- 9. Ivanenkov and Menon, 1999, Biochem. et Biophys. Acta 1448: 463-472.
- 10. Ivanenkov and Menon, 1999, Biochem. et Biophys. Acta 1448: 450-462.
- 11. Kim et al., 1999, Cancer Immunol. Immunother. 47: 257.
- 12. Osaki et al., 1999, Gene Ther. 6: 808.

- 13. Pittenger et al., 1999, *Science 284*: 143.
- 14. Nishioka et al., 1999, Cancer Res. 59: 4035.

RECEIVED

15. Shwarze et al., 1999, *Science 285*: 1569-1572.

MAR 0 6 2001

16. Vocero-Akbani et al., 1999, *Nat. Med. 5*: 29-33.

TECH CENTER 1600/2900

- 17. Yamabe et al., 1999, Gene Ther. 6: 1952-1959.
- 18. Derossi et al., 1998, *Trends in Cell Biol.* 8: 84-87.
- 19. Ghivizzani et al., 1998, Proc. Natl. Acad. Sci. USA 95: 4613.
- 20. Mangeney and Heidmann, 1988, Proc. Natl. Acad. Sci. USA 95: 14920.
- 21. Nagahara et al., 1998, Nat. Med. 4: 1449-1452.
- 22. Noffz et al., 1988, J. Immunol. 160: 345.
- 23. Osaki et al., 1998, *J. Immunol. 160*: 1742.
- 24. Sakai et al., 1998, Arthritis Rheum. 41:1251-1257.
- 25. Villaverde et al., 1998, *Biotechnol. and Bioeng.* 59: 294-301.
- 26. Wakisaka et al., 1998, Clin. Exp. Immunol. 114: 119-128.
- 27. Cayeux et al., 1997, *J. Immunol. 158*: 2834.
- 28. Elliot and O'Hare, 1997, *Cell 188*: 223-233.
- 29. Felgner, 1997, Sci. Am. 276: 102-106.
- 30. Ghivizzani et al., 1997, *Gene Ther.* 4: 977.
- 31. Ghivizzani et al., 1997, *J. immunol. 159*: 3604.
- 32. Kato and Sugiyams, 1997, Crit. Rev. Ther. Drug Carrier Syst. 14: 287-331.
- 33. Kirpotin et al., 1997, *Biochemistry* 36: 66-75.

- 34. Knudsen and Nielsen, 1997, Anticancer Drugs 8: 113-118.
- 35. Spragg et al., 1997, *Proc. Natl. Acad. Sci. USA* 94: 8795-8800.
- 36. Szardenings et al., 1997, *J. Biol. Chem.* 272: 27943-27948.
- 37. Vives et al., 1997, *J. Biol. Che.*, 272: 16010-16017.
- 38. Barry and Johnson, 1996, *Nat. Med. 2*: 299-305.
- 39. Berlose et al., 1996, Eur. J. Biochem. 242: 372.
- 40. Derossi et al., 1996, J. Biochem. 217: 18188-18193.
- 41. Fitzgerald, 1996, Semin. Cancer Biol. 7: 87-95.
- 42. Moy etl al., 1996, Mol. Biotechnol. 6: 105-113.
- 43. Nita et al., 1996, Arthritis Rheum. 39: 820.
- 44. Ohno et al., 1996, *J. Immunol. 156*: 3875.
- 45. Sato et al., 1996, *Adv. Drug Deliv. Rev. 19*: 445-467.
- 46. Zeigler et al., 1996, *Transplantation 61*: 812-817.
- 47. Wickham et al., 1995, Gene Ther. 2: 750-756.
- 48. Berns and Giraud, 1995, Ann. N. Y. Acad. Sci. 772: 95-104.
- 49. Hancberg et al., 1995, *Adv. Exp. Med. Biol. 371A*: 107-109.
- 50. Smith, 1995, Ann. Rev. Microbiol. 49: 807-838.
- 51. Yang et al., 1995, *J. Virol.* 69: 2004-2015.
- 52. Fawell et al., 1994, Proc. Natl. Acad. Sci. USA 91: 664-668.
- 53. Kuzel and Rosen, 1994, *Curr. Opin. Oncol. 6*: 622-626.
- 54. Sreerama and Woody, 1994, *Biochemisty 33*: 10022-10025.

- 55. Weitzman et al., 1994, *Proc. Natl. Acad. Sci. USA 91*: 5808-5812.
- 56. Kozarsky and Wilson, 1993, Curr. Opin. Genet. Dev. 3: 49-50.

RECEIVED

57. Miller et al., 1993, *Lab Invest.* 68: 129-145.

MAR 0 6 2001

58. Mulligan, 1993, *Science 260*: 926-932.

TECH CENTER 1600/2900

- 59. Vitetta et al., 1993, *Immunol. Today 14*: 252-259.
- 60. Zatloukal et al., 1993, Gene 135: 199-207.
- 61. Wagner et al., 1992, Proc. Natl. Acad. Sci. 89: 6099-6103.
- 62. Wagner et al., 1992, Proc Natl. Acad. Sci. 89: 7934-7938.
- 63. Evans, 1991, Agents Actions Suppl. 32: 135-152.
- 64. Curiel et al., 1991, Proc. Natl. Acad. Sci. 88: 8850-8854.
- 65. Basu, 1990, Biochem. Pharmacol. 40: 1941-1946.
- 66. Wu and Wu, 1989, J. Biol. Chem. 264: 16985-16987.
- 67. Frankel and Pabo, 1988, *Cell* 55: 1189-1193.
- 68. Green and Lowenstein, 1988, *Cell* 55: 1179-1188.
- 69. Wu and Wu, 1988, *J. Biol. Chem.* 263: 14621-14624.
- 70. Wu and Wu, 1987, *J. Biol. Chem.* 262: 4429-4432.
- 71. Bayer et al., 1976, *Histchem. Cytochem.* 24: 933-939.

Identification of the above-listed references is not to be construed as an admission by the Applicants or the attorneys of the Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing

references and that the references be made of record in the file history of the abovementioned application.

No fee is believed to be required in connection with this communication.

However, if a fee is required, the Commissioner is hereby authorized to charge the fee to

Deposit Account No. 02-4377. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: February 28, 2001

Rochelle K. Seide

Patent Office Reg. No. 32,300

Attorney for Applicants (212) 408-2626

Alicia A. Russo Patent Office Reg. No. 46,192

Agent for Applicants (212)408-2627

Enclosures

Page 1 of 6 Atty. Docket No. Form PTO-1449 U.S. Department of Commerce Serial No. (REV. 2-82) Patent and Trademark Office AP32573-A-A 09/653,182 Applicant INFORMATION DISCLOSURE STATEMENT Robbins et al. **BY APPLICANT** (Use several sheets if necessary) Filing Date Group August 31, 2000 1645 **U.S. PATENT DOCUMENTS** Filing Date *Exam. Date Name Class Subclass ifAppropriate Init. Document No. 08/16/94 Schatz et al. FOREIGN PATENT DOCUMENT Translator Date Country Class SubClass Yes No Document No. 03/04/99 PCT 8 5 02/11/99 PCT 4 2 9 0 6 5 03/24/99 0 9 0 3 4 () 8 Europe 11/19/98 PCT 9 8 5 8 2 PCT 5 11/19/98 8 5 1 OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.) Schwarze and Dowdy, 2000, TIPS 21: 45-48. Elliot and O'Hare, 2000, J. Virol. 74: 2131-2141. Branden et al., 1999, Nat. Biotechnol. 17: 784-787. Brown & Wauters, 1999, Cancer Res. 59: 1391-1399. Ellerby et al., 1999, Nat. Med. 5: 1032. Derer et al., 1999, J. Mol. Med. 77: 609-613. 6 Gambotto et al., 1999, Cancer Gene Ther. 6: 45.

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

Date Considered

conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce MAS § 7 (REV. 2-82) Patent and Trademark Office 3.

Atty. Docket	No.
AP32573	A-A

Filing Date

OFFE

Serial No. 09/653.182

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant
Robbins et al.

August 31, 2000

Group 1645

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.) Hiroshi et al., 1999, Gene Ther. 6: 1988. 8 9 Ivanenkov and Menon, 1999, Biochem. et Biophys. Acta 1448: 463-472. Ivanenkov and Menon, 1999, Biochem. et Biophys. Acta 1448: 450-462 10 Kim et al., 1999, Cancer Immunol. Immunother. 47: 257. 11 12 Osaki et al., 1999, Gene Ther. 6: 808. 13 Pittenger et al., 1999, Science 284: 143. 14 Nishioka et al., 1999, Cancer Res. 59: 4035. 15 Shwarze et al., 1999, Science 285: 1569-1572. Vocero-Akbani et al., 1999, Nat. Med. 5: 29-33. 16 Yamabe et al., 1999, Gene Ther 6: 1952-1959. 17 Derossi et al., 1998, Trends in Cell Biol. 8: 84-87. 18 Ghivizzani et al., 1998, Proc. Natl. Acad. Sci. USA 95: 4613 19 20 Mangeney and Heidmann, 1988, Proc. Natl. Acad. Sci. USA 95: 14920.

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	1	7.	
•	5 ,	<i>i</i> ~	

Form PTO-14	49 U.S. Department of Commerce
(REV. 2-82)	Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(Use several sheets if necessary)

Atty. Docket No. AP32573-A-A	Serial No. 09/653,182
Applicant Robbins et al.	
Filing Date August 31, 2000	Group 1645

21	Nagahara et al., 1998, Nat. Med. 4: 1449-1452.
22	Noffz et al., 1988, J. Immunol. 160: 345.
23	Osaki et al., 1998, <i>J. Immunol. 160</i> : 1742.
24	Sakai et al., 1998, <i>Arthritis Rheum. 41</i> :1251-1257.
25	Villaverde et al., 1998, <i>Biotechnol. and Bioeng.</i> 59: 294-301.
26	Wakisaka et al., 1998, <i>Clin. Exp. Immunol. 114</i> : 119-128.
27	Cayeux et al., 1997, <i>J. Immunol. 158</i> : 2834.
28	Elliot and O'Hare, 1997, Cell 188: 223-233.
29	Felgner, 1997, Sci. Am. 276: 102-106.
30	Ghivizzani et al., 1997, Gene Ther. 4: 977.
31	Ghivizzani et al., 1997, <i>J. immunol. 159</i> : 3604.
32	Kato and Sugiyams, 1997, Crit. Rev. Ther. Drug Carrier Syst. 14: 287-331.
33	Kirpotin et al., 1997, Biochemistry 36: 66-75.

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
AP32573-A-A	09/653,182

Applicant Robbins et al.

Filing Date Group
August 31, 2000 1645

34	Knudsen and Nielsen, 1997, Anticancer Drugs 8: 113-118.
35	Spragg et al., 1997, <i>Proc. Natl. Acad. Sci. USA 94</i> : 8795-8800.
36	Szardenings et al., 1997, <i>J. Biol. Chem. 272</i> : 27943-27948.
37	Vives et al., 1997, <i>J. Biol. Che,. 272</i> : 16010-16017.
38	Barry and Johnson, 1996, <i>Nat. Med. 2</i> : 299-305.
39	Berlose et al., 1996, Eur. J. Biochem. 242: 372.
40	Derossi et al., 1996, <i>J. Biochem. 217</i> : 18188-18193.
41	Fitzgerald, 1996, Semin. Cancer Biol. 7: 87-95.
42	Moy etl al., 1996, <i>Mol. Biotechnol.</i> 6: 105-113.
43	Nita et al., 1996, Arthritis Rheum. 39: 820.
44	Ohno et al., 1996, <i>J. Immunol. 156</i> : 3875.
45	Sato et al., 1996, Adv. Drug Deliv. Rev. 19: 445-467.
46	Zeigler et al., 1996, Transplantation 61: 812-817.

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

(P	\	۳	<u> </u>	UO/2

Form PTO-14	49 U.S. Dep	artment of Commerce
(REV. 2-82)	Patent and	Trademark Office

INFORMATION DISCLOSURE STATEMENTS BY APPLICANT

(Use several sheets if necessary)

	Atty. Docket No. AP32573-A-A	Serial No. 09/653,182
•	Applicant Robbins et al.	

Filing Date Group
August 31, 2000 1645

47	Wickham et al., 1995, Gene Ther. 2: 750-756.
48	Berns and Giraud, 1995, Ann. N. Y. Acad. Sci. 772: 95-104.
49	Haneberg et al., 1995, Adv. Exp. Med. Biol. 371A: 107-109.
50	Smith, 1995, Ann. Rev. Microbiol. 49: 807-838.
51	Yang et al., 1995, J. Virol. 69: 2004-2015.
52	Fawell et al., 1994, Proc. Natl. Acad. Sci. USA 91: 664-668.
53	Kuzel and Rosen, 1994, Curr. Opin. Oncol. 6: 622-626.
54	Sreerama and Woody, 1994, Biochemisty 33: 10022-10025.
55	Weitzman et al., 1994, Proc. Natl. Acad. Sci. USA 91: 5808-5812.
56	Kozarsky and Wilson, 1993, Curr. Opin. Genet. Dev. 3: 49-50.
57	Miller et al., 1993, Lab Invest. 68: 129-145.
58	Mulligan, 1993, <i>Science 260</i> : 926-932.
59	Vitetta et al., 1993, Immunol. Today 14: 252-259.

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. AP32573-A-A	Serial No. 09/653,182	
Applicant Robbins et al.		
Filing Date August 31, 2000	Group 1645	

60	Zatloukal et al., 1993, Gene 135: 199-207.
61	Wagner et al., 1992, <i>Proc. Natl. Acad. Sci.</i> 89: 6099-6103.
62	Wagner et al., 1992, <i>Proc. Natl. Acad. Sci.</i> 89: 7934-7938.
63	Evans, 1991, Agents Actions Suppl. 32: 135-152.
64	Curiel et al., 1991, Proc. Natl. Acad. Sci. 88: 8850-8854.
65	Basu, 1990, <i>Biochem. Pharmacol.</i> 40: 1941-1946.
66	Wu and Wu, 1989, J. Biol. Chem. 264: 16985-16987.
67	Frankel and Pabo, 1988, <i>Cell 55</i> : 1189-1193.
68	Green and Lowenstein, 1988, <i>Cell 55</i> : 1179-1188.
69	Wu and Wu, 1988, <i>J. Biol. Chem. 263</i> : 14621-14624.
70	Wu and Wu, 1987, <i>J. Biol. Chem. 262</i> : 4429-4432.
71	Bayer et al., 1976, <i>Histchem. Cytochem. 24</i> : 933-939.

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered